Publications by authors named "L A Ayuso"
Objective: To ascertain the changes of serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) values in relapsing-remitting multiple sclerosis (RRMS) patients treated with ocrelizumab and their association with treatment response.
Methods: Multicenter prospective study including 115 RRMS patients initiating ocrelizumab treatment between February 2020 and March 2022 followed during a year. Serum samples were collected at baseline and every 3 months to measure sNfL and sGFAP levels using single-molecule array (SIMOA) technology.
Article Synopsis
- The study focuses on identifying individuals with radiologically isolated syndrome (RIS) who may develop multiple sclerosis (MS), emphasizing the importance of early detection for treatment planning.
- The research involved 21 RIS participants, where baseline assessments including multifocal Visual Evoked Potentials (mfVEP) and MRI were conducted, followed by tracking their condition over 24 months.
- Findings showed that certain mfVEP measures, such as reduced amplitude and longer latency, significantly indicated a higher risk of these individuals converting to MS, proposing mfVEP as a valuable predictive tool.
Article Synopsis
- - The study explored how serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels could predict worsening disability in multiple sclerosis (MS), enrolling 725 patients across 13 European hospitals from 1994 to 2023.
- - Higher levels of sNfL were significantly associated with increased risks of relapse-associated worsening (RAW), progression independent of relapse activity (PIRA), and reaching an Expanded Disability Status Scale (EDSS) score of 3, while elevated sGFAP levels were linked to a higher risk of reaching the EDSS score.
- - Combining both sNfL and sGFAP levels indicated that low values represented low risk for worsening
Background: Dimethyl fumarate (DMF) has demonstrated efficacy in phase III studies. However, real-world data are still limited.
Objective: The objective of this study was to describe the profile of patients who receive DMF and to assess the effectiveness of DMF regarding relapses, disability progression, magnetic resonance imaging activity, and NEDA (No Evidence Disease Activity)-3 status in a Spanish population in a real-world setting.